Aytu BioPharma (NASDAQ:AYTU) Releases Earnings Results, Misses Estimates By $0.37 EPS

Aytu BioPharma (NASDAQ:AYTU) issued its quarterly earnings data on Thursday. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.37), Zacks reports. The company had revenue of $17.98 million for the quarter. Aytu BioPharma had a negative return on equity of 31.31% and a negative net margin of 14.60%.

Aytu BioPharma Trading Down 17.2 %

Shares of NASDAQ:AYTU traded down $0.49 on Friday, hitting $2.36. The company had a trading volume of 237,675 shares, compared to its average volume of 20,737. The company has a market cap of $14.09 million, a PE ratio of -0.90 and a beta of -1.43. The business has a 50 day moving average of $2.52 and a 200 day moving average of $2.82. Aytu BioPharma has a 52-week low of $1.87 and a 52-week high of $3.50.

About Aytu BioPharma

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.